---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-242514"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:24:16.963200+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics retracts false claim about IntraBio's Phase 2 study for NALL in A-T

## Summary
- Quince stated on Oct 2 Investor Day that IntraBio's NALL Phase 2 failed all endpoints in A-T; now retracts that statement.
- The statement was based on a different study (EJPN Article), not the IntraBio Phase 2 study; Quince removed it from materials.
- The EJPN Article found NALL failed to improve motor function significantly but improved some symptoms (e.g., nausea, constipation).
- Quince advises investors not to rely on the retracted statement; underlying facts did not support the original claim.

## SEC filing metadata
- accession: 0001193125-25-242514
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312525242514/0001193125-25-242514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312525242514/d75404d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-242514
- JSON: https://secwatch.observer/filing/0001193125-25-242514.json
- Plain text: https://secwatch.observer/filing/0001193125-25-242514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.